Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Solvents

Methylated B12 10mg (10mL)

$77Per Unit

High-concentration B12 liquid formulation with purity verification for research applications.

Lot B12-2025-05A · COA on request
10mg/10mL liquid vial
2–8°C

5 × $77.00 = $385.00 $250.25 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

Methylated B12 10mg (10mL)

$250.25 for 5 · 35% off

Research use only
Methylated B12 10mg (10mL) research packaging
10mg/10mL liquid vial
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot B12-2025-05A) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

Methylcobalamin (vitamin B12)(Methylcobalamin, Methyl B12, Vitamin B12, B12)

Regulatory status
A form of vitamin B12. Very high doses have been tested as a drug for early ALS in a phase 3 trial in Japan. Research material here is not an approved drug product.
Strongest evidence
One randomized phase 3 trial (early ALS); vitamin B12 deficiency is well characterized
Overview

Methylcobalamin is a form of vitamin B12, the vitamin with central roles in DNA synthesis, methylation and mitochondrial metabolism. Separately from its role as a vitamin, ultrahigh doses have been studied as a possible treatment for amyotrophic lateral sclerosis (ALS).

What researchers study it for
  • Early-stage ALS (ultrahigh-dose injections, phase 3)
  • Vitamin B12 deficiency
Mechanism

Vitamin B12 supports DNA synthesis, methylation and mitochondrial metabolism. How ultrahigh doses might slow ALS was not established by the trial.

Evidence (2)
  1. Human · randomized trial

    JETALS phase 3 trial (JAMA Neurol 2022)

    130 people with ALS diagnosed within a year of onset, 16 weeks, double-blind against placebo at 25 centres in Japan. Functional decline on the ALSFRS-R scale was 1.97 points smaller with methylcobalamin, and adverse events were similar in both groups.[1][2]

  2. Review

    Vitamin B12 deficiency (Nat Rev Dis Primers 2017)

    Subclinical B12 deficiency affects between 2.5% and 26% of the general population depending on the definition, most often older people; it is managed with high-dose oral or injected B12.[3]

Limitations of the evidence
  • The ALS benefit was shown in early-stage patients with a moderate rate of progression, over 16 weeks.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (3)
  1. 1.Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialOki R et al. JAMA Neurol. 2022 Human · randomized trial
  2. 2.Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (JETALS)ClinicalTrials.gov NCT03548311 Trial registry
  3. 3.Vitamin B12 deficiencyGreen R et al. Nat Rev Dis Primers. 2017 Review
Every published studyPubMed search: methylcobalamin(opens in a new tab)Every registered trialClinicalTrials.gov search: methylcobalamin(opens in a new tab)

Reviewed 2026-10-10. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.